QQQ   351.27 (+0.94%)
AAPL   179.40 (+1.21%)
MSFT   331.45 (+0.93%)
META   271.47 (+2.55%)
GOOGL   122.95 (+0.07%)
AMZN   122.45 (+1.55%)
TSLA   207.13 (+1.57%)
NVDA   396.43 (+4.78%)
NIO   7.52 (-0.13%)
BABA   83.05 (+4.40%)
AMD   119.71 (+1.27%)
T   15.84 (+0.70%)
F   12.10 (+0.83%)
MU   69.20 (+1.47%)
CGC   0.83 (-0.51%)
GE   104.65 (+3.07%)
DIS   88.55 (+0.67%)
AMC   4.53 (+0.67%)
PFE   37.96 (-0.16%)
PYPL   63.06 (+1.73%)
NFLX   402.31 (+1.79%)
QQQ   351.27 (+0.94%)
AAPL   179.40 (+1.21%)
MSFT   331.45 (+0.93%)
META   271.47 (+2.55%)
GOOGL   122.95 (+0.07%)
AMZN   122.45 (+1.55%)
TSLA   207.13 (+1.57%)
NVDA   396.43 (+4.78%)
NIO   7.52 (-0.13%)
BABA   83.05 (+4.40%)
AMD   119.71 (+1.27%)
T   15.84 (+0.70%)
F   12.10 (+0.83%)
MU   69.20 (+1.47%)
CGC   0.83 (-0.51%)
GE   104.65 (+3.07%)
DIS   88.55 (+0.67%)
AMC   4.53 (+0.67%)
PFE   37.96 (-0.16%)
PYPL   63.06 (+1.73%)
NFLX   402.31 (+1.79%)
QQQ   351.27 (+0.94%)
AAPL   179.40 (+1.21%)
MSFT   331.45 (+0.93%)
META   271.47 (+2.55%)
GOOGL   122.95 (+0.07%)
AMZN   122.45 (+1.55%)
TSLA   207.13 (+1.57%)
NVDA   396.43 (+4.78%)
NIO   7.52 (-0.13%)
BABA   83.05 (+4.40%)
AMD   119.71 (+1.27%)
T   15.84 (+0.70%)
F   12.10 (+0.83%)
MU   69.20 (+1.47%)
CGC   0.83 (-0.51%)
GE   104.65 (+3.07%)
DIS   88.55 (+0.67%)
AMC   4.53 (+0.67%)
PFE   37.96 (-0.16%)
PYPL   63.06 (+1.73%)
NFLX   402.31 (+1.79%)
QQQ   351.27 (+0.94%)
AAPL   179.40 (+1.21%)
MSFT   331.45 (+0.93%)
META   271.47 (+2.55%)
GOOGL   122.95 (+0.07%)
AMZN   122.45 (+1.55%)
TSLA   207.13 (+1.57%)
NVDA   396.43 (+4.78%)
NIO   7.52 (-0.13%)
BABA   83.05 (+4.40%)
AMD   119.71 (+1.27%)
T   15.84 (+0.70%)
F   12.10 (+0.83%)
MU   69.20 (+1.47%)
CGC   0.83 (-0.51%)
GE   104.65 (+3.07%)
DIS   88.55 (+0.67%)
AMC   4.53 (+0.67%)
PFE   37.96 (-0.16%)
PYPL   63.06 (+1.73%)
NFLX   402.31 (+1.79%)

Rain Oncology (RAIN) Stock Forecast, Price & News

$1.12
+0.01 (+0.95%)
(As of 03:46 PM ET)
Compare
Today's Range
$1.04
$1.15
50-Day Range
$1.09
$9.93
52-Week Range
$0.94
$14.48
Volume
1.05 million shs
Average Volume
798,004 shs
Market Capitalization
$40.74 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.00

Rain Oncology MarketRank™ Forecast

Analyst Rating
Hold
2.42 Rating Score
Upside/​Downside
1,445.5% Upside
$17.00 Price Target
Short Interest
Healthy
6.20% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.36mentions of Rain Oncology in the last 14 days
Based on 20 Articles This Week
Insider Trading
Selling Shares
$1.24 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.92) to ($1.34) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.62 out of 5 stars

Medical Sector

197th out of 1,980 stocks

Pharmaceutical Preparations Industry

77th out of 978 stocks


RAIN stock logo

About Rain Oncology (NASDAQ:RAIN) Stock

Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinical trial for intimal sarcoma, as well as RAD52 which is in preclinical trials for tumors, including breast, ovarian, pancreatic, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.

Receive RAIN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rain Oncology and its competitors with MarketBeat's FREE daily newsletter.

RAIN Stock News Headlines

Graphite Shortage Could Derail the $7 Trillion EV Transition
Graphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.
Rain Oncology (NASDAQ:RAIN) Cut to Neutral at Roth Capital
Graphite Shortage Could Derail the $7 Trillion EV Transition
Graphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.
See More Headlines

RAIN Price History

RAIN Company Calendar

Last Earnings
5/11/2023
Today
6/01/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RAIN
Fax
N/A
Employees
44
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$17.00
High Stock Price Forecast
$24.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+1,411.1%
Consensus Rating
Hold
Rating Score (0-4)
2.42
Research Coverage
13 Analysts

Profitability

Net Income
$-75,720,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.60 per share

Miscellaneous

Free Float
28,400,000
Market Cap
$40.91 million
Optionable
Not Optionable
Beta
0.04

Key Executives

  • Mr. Avanish Vellanki M.B.A. (Age 47)
    Co-Founder, CEO & Chairman
    Comp: $817.59k
  • Dr. Robert C. Doebele M.D. (Age 50)
    Ph.D., Co-Founder, Member of Scientific Advisory Board, Pres & Chief Scientific Officer
    Comp: $619.14k
  • Dr. Richard P. Bryce (Age 65)
    Exec. VP & Chief Medical Officer
    Comp: $496.25k
  • Mr. Nelson D. Cabatuan (Age 44)
    Sr. VP of Fin. & Admin.
  • Ms. Theresa O'Connell M.S.
    Director of Corp. Devel. & Operations
  • Ms. Vijaya Tirunagaru Ph.D.
    Sr. VP & Head of Research
  • Mr. Lucio Tozzi (Age 58)
    Sr. VP of Clinical Operations
  • Ms. Buenaflor Nicolas M.P.H.
    VP, Head Global Drug Safety & Pharmacovigilance
  • Dr. Nora Ku M.D.
    MD & VP of Clinical Devel.
  • Dr. Mehdi Paborji Ph.D. (Age 67)
    Sr. VP of Technical Operations













RAIN Stock - Frequently Asked Questions

Should I buy or sell Rain Oncology stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rain Oncology in the last year. There are currently 9 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" RAIN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RAIN, but not buy additional shares or sell existing shares.
View RAIN analyst ratings
or view top-rated stocks.

What is Rain Oncology's stock price forecast for 2023?

13 analysts have issued 12-month price targets for Rain Oncology's shares. Their RAIN share price forecasts range from $11.00 to $24.00. On average, they expect the company's stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 1,411.1% from the stock's current price.
View analysts price targets for RAIN
or view top-rated stocks among Wall Street analysts.

How have RAIN shares performed in 2023?

Rain Oncology's stock was trading at $8.00 at the beginning of the year. Since then, RAIN shares have decreased by 85.9% and is now trading at $1.1250.
View the best growth stocks for 2023 here
.

When is Rain Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our RAIN earnings forecast
.

How were Rain Oncology's earnings last quarter?

Rain Oncology Inc. (NASDAQ:RAIN) released its earnings results on Thursday, May, 11th. The company reported ($0.56) earnings per share for the quarter, topping analysts' consensus estimates of ($0.57) by $0.01.

What ETF holds Rain Oncology's stock ?

Horizon Kinetics Medical ETF holds 25,000 shares of RAIN stock, representing 0.97% of its portfolio.

When did Rain Oncology IPO?

(RAIN) raised $126 million in an initial public offering on Friday, April 23rd 2021. The company issued 7,400,000 shares at $16.00-$18.00 per share. Goldman Sachs, Citigroup, Piper Sandler and Guggenheim Securities acted as the underwriters for the IPO.

What is Rain Oncology's stock symbol?

Rain Oncology trades on the NASDAQ under the ticker symbol "RAIN."

Who are Rain Oncology's major shareholders?

Rain Oncology's stock is owned by many different institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (4.53%), GMT Capital Corp (2.27%), Sectoral Asset Management Inc. (1.33%), FMR LLC (0.96%), Ghost Tree Capital LLC (0.69%) and Alyeska Investment Group L.P. (0.55%). Insiders that own company stock include Aaron I Davis, Boxer Capital, Llc, Bvf Partners L P/Il, Cormorant Asset Management, Lp, Franklin M Berger, Perceptive Advisors Llc and Value Fund L P Biotechnology.
View institutional ownership trends
.

How do I buy shares of Rain Oncology?

Shares of RAIN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rain Oncology's stock price today?

One share of RAIN stock can currently be purchased for approximately $1.13.

How much money does Rain Oncology make?

Rain Oncology (NASDAQ:RAIN) has a market capitalization of $40.91 million. The company earns $-75,720,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis.

How can I contact Rain Oncology?

The official website for the company is www.rainthera.com. The company can be reached via phone at 510-953-5559 or via email at bob@lifesciadvisors.com.

This page (NASDAQ:RAIN) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -